Garry E Menzel Tcr2 Therapeutics Inc. (TCRR) insider trading activity

Garry E Menzel is President and CEO of TCR2 THERAPEUTICS INC.. Currently has a direct ownership of 0 shares of TCRR, which is worth approximately $0. The most recent transaction as insider was on Jun 01, 2023, when has been sold 138,871 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Garry E Menzel Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 01 2023	SELL Sale (or disposition) back to the issuer	-	138,871 Reduced 100.0%	0 Common Stock
Dec 13 2022	SELL Open market or private sale	$11,660 $1.06 p/Share	11,000 Reduced 7.34%	138,871 Common Stock
Dec 12 2022	SELL Open market or private sale	$11,674 $1.1 p/Share	10,613 Reduced 6.61%	149,871 Common Stock
Dec 09 2022	SELL Open market or private sale	$11,667 $1.13 p/Share	10,325 Reduced 6.04%	160,484 Common Stock
Dec 08 2022	SELL Open market or private sale	$11,642 $1.25 p/Share	9,314 Reduced 5.17%	170,809 Common Stock
Dec 07 2022	SELL Open market or private sale	$11,662 $1.28 p/Share	9,111 Reduced 4.81%	180,123 Common Stock
Dec 06 2022	SELL Open market or private sale	$20,096 $1.35 p/Share	14,886 Reduced 7.29%	189,234 Common Stock
Dec 05 2022	SELL Open market or private sale	$11,686 $1.37 p/Share	8,530 Reduced 4.01%	204,120 Common Stock
Dec 02 2022	SELL Open market or private sale	$11,687 $1.39 p/Share	8,408 Reduced 3.8%	212,650 Common Stock
Dec 01 2022	BUY Exercise of conversion of derivative security	-	221,058 Added 50.0%	221,058 Common Stock
Jul 05 2022	SELL Bona fide gift	-	180,932 Reduced 100.0%	0 Common Stock
Feb 28 2022	BUY Grant, award, or other acquisition	$3,277 $2.3 p/Share	1,425 Added 0.78%	180,932 Common Stock
Dec 09 2021	BUY Exercise of conversion of derivative security	$129,500 $0.74 p/Share	175,000 Added 49.36%	179,507 Common Stock
Aug 31 2021	BUY Grant, award, or other acquisition	$6,018 $14.26 p/Share	422 Added 8.56%	4,507 Common Stock
Feb 28 2021	BUY Grant, award, or other acquisition	$11,058 $16.12 p/Share	686 Added 14.38%	4,085 Common Stock
Aug 31 2020	BUY Grant, award, or other acquisition	$11,433 $10.1 p/Share	1,132 Added 24.98%	3,399 Common Stock

Also insider at

STOK

Stoke Therapeutics, Inc. Healthcare

BDTX

Black Diamond Therapeutics, Inc. Healthcare

ADAP

Adaptimmune Therapeutics PLC Healthcare

Director

GEM

Garry E Menzel

President and CEO

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TCRR shares.

Notify only if

Value

Insider Trading

Get notified when an Tcr2 Therapeutics Inc. insider buys or sells TCRR shares.

Notify only if

Operation

Value

Type

News

Receive news related to TCR2 THERAPEUTICS INC.

Track Activities on TCRR

Account